<DOC>
	<DOCNO>NCT00262210</DOCNO>
	<brief_summary>* AIMS OF THE STUDY 1 . To test steroid-free chemotherapeutic regimen decrease risk HBV reactivation hepatitis development HBsAg ( + ) carrier . 2 . To compare efficacy steroid-free chemotherapeutic regimen steroid-containing regimen term lymphoma control . 3 . To study change activity HBV hepatotropic virus course chemotherapy .</brief_summary>
	<brief_title>A Comparative Study Non-Hodgkin 's Lymphoma Hepatitis B Virus Carriers</brief_title>
	<detailed_description>* TREATMENT PLANS FOR FIRST-LINE AND SECOND LINE CHEMOTHERAPY 1 . First-line Chemotherapy 1.1 PACE ACE Treatment Scheme PACE ACE* Cyclophosphamide 650 mg/m2 , i.v . Day 1 Epirubicin 60 mg/m2 , i.v . Day 1 Etoposide 55 mg/m2/d , i.v . Day 1-3 Prednisolone 60 mg/m2/d , p.o . Day 1-7 - For ACE , prednisolone omit . 1.2 Courses repeat every 21 day . 1.3 For patient CR , give least 2 additional course minimum 6 course . 1.4 For patient PR SD , may change second-line chemotherapy tumor shrinkage two consecutive courses.Local radiotherapy allow residual localized tumor . 1.5 For patient PD , change second-line chemotherapy . 2 . Second-line Chemotherapy : For patient fail steroid-containing steroid- free chemotherapy , respective steroid-containing steroid-free salvage chemotherapy use . 2.1 VIMP VIM Treatment Scheme VIMP VIM* VP-16 100 mg/m2/d , i.v . Day 1,3,5 Ifosfamide 1 gm/m2/d , i.v . Day 1-5 MTX 30 mg/m2/d , i.v . Day 1,5 Prednisolone 60 mg/m2/d , P.O . Day 1-7 - For VIM , prednisolone omit . Repeated every 21 day . Mesna urinary tract protection need : Mesna 100 mg/m2 bolus inject immediately infusion first-day ifosfamide , 500mg/m2/day infuse 5 day ifosfamide . 2.2 Infusional CDE + P ( ICDE + P ) Infusional CDE ( ICDE ) Treatment Scheme ICDE+P ICDE* Cyclophosphamide 187.5 mg/m2/d , continuous i.v . infusion Day 1-4 Epirubicin 20 mg/m2/d , continuous i.v . infusion Day 1-4 Etoposide 60 mg/m2/d , continuous i.v . infusion Day 1,4 Prednisolone 60 mg/m2/d , P.O . Day 1-7 - For ICDE , prednisolone omit . Repeated every 21 day . - Cyclophosphamide epirubicin mix 500ml 5 % D/W , infuse together . Etoposide dissolve another 500ml 5 % D/W , infuse separate line . 3.0 DOSE MODIFICATION 3.1 Hematological Toxicity* Drug administration postpone one week full hematological recovery ( AGC ＞ 2,000/mm3 Platelet ＞ 100,000/mm3 ) prior course scheduled treatment day . Full dose give soon hematological recovery document . If another one week , i.e . two week due day , recovery still incomplete , treatment may start dosage drug reduce accord follow schedule regimen : AGC*/mm3Platelet/mm3 1,500-2,00075,000-100,000 1,000-1,49950,000-74,999 ＜1,000＜50,000 Cyclophosphamide 80 % 60 % ** Epirubicin 80 % 60 % ** VP-16 80 % 60 % ** Ifosfamide 80 % 60 % ** MTX 80 % 60 % ** - Growth factor ( G-CSF , GM-CSF ) allow used patient prolonged myelosuppression , influence schedule dose- modification illustrate . - Postpone another week . If count remain AGC ＜ 1000 Platelet ＜ 50,000 , growth factor may use juncture , i.e . 2 week due day . Patients study still AGC ＜ 1,000 Platelet ＜ 50,000 , 3 week due day . 3.2 Hepatotoxicity For patient normal abnormal prechemotherapy serum ALT , hepatitis hepatitis flare-up define threefold great increase serum ALT level exceed 100 IU/L . The hepatitis hepatitis flare-up attributed reactivation chronic hepatitis B sudden elevation ( ＞ 10-fold ) serum HBV DNA level reappearance HBV DNA HBeAg serum . Since serum HBV DNA data readily available hospital , patient hepatitis hepatitis flare-up consider HBV reactivation prove otherwise . Cross-over steroid-free arm subsequent treatment allow study . For patient minor hepatic dysfunction ( Total Bilirubin ＜3.0 mg/dl ALT ＜200 I.U./L ) , full-dose chemotherapy recommend schedule treatment date without delay . For patient severe hepatic dysfunction ( total bilirubin ≧ 3.0 mg/dl ALT ≧ 200 I.U./L ) , subsequent course postpone 1 week dosage modify following value remain abnormal 1 week : Total Bilirubin ( mg/dl ) ＜3.0 3.0 - 4.9 5.0 - 7.5 ＞7.5 ALT ( I.U./L ) ＜200 200 - 399 400 - 800 ＞800 Epirubicin 100 % 75 % 50 % * - Wait recovery serum level value . Patients study Bil ＞ 7.5 ALT ＞ 800 , 3 week due day . 3.3 Gastrointestinal Toxicity In case severe ( ≧ ECOG grade III ) anorexia , nausea , vomit , diarrhea , stomatitis abdominal pain , therapy delay improvement symptom ≦ GrII . Patient study ≧ GrIII toxicity persist ≧ 3 week due day . Patients allow use H3-blockers subsequent course severe nausea vomiting . If gastrointestinal toxicity still ≧ Gr II next course , dose cyclophosphamide , epirubicin VP-16 reduce 25 % subsequent course . If episode severe reaction , dose escalate back 100 % . 3.4 Cardiotoxicity In case ECOG grade II cardiotoxicity , epirubicin reduce 50 % . If cardiotoxicity resolve , dose may carefully escalate i.e. , increase 10-25 % dose time , subsequent course . If severe ( ≧ ECOG grade III ) cardiotoxicity develop , epirubicin discontinue use subsequent course . 3.5 In event multiple toxicity , dose modification make base guideline require great reduction dos . 4 . CRITERIA FOR REMOVAL FROM STUDY All patient still complete protocol treatment ( 1st-line 2nd-line ) continuously followed-up study end point . Patients remove study major violation protocol due follow reason : 4.1 Refuse treatment . 4.2 Unable receive due treatment either severe toxicity reason . 4.3 Inadvertent cross-over opposite arm ( steroid-containing steroid-free ) treatment .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>1 . Histologically proven NHL , intensive chemotherapy consider treatmentofchoice . 2 . HBsAgpositive . 3 . No previous chemotherapy radiotherapy . 4 . No concurrent radiotherapy . AGC ≧ 2,000/mm3 , Platelet ≧ 100,000/mm3 peripheral blood . 5 . Total bilirubin ≦ 2.5 mg/dl . Alanine aminotransferase ( SGPT ) ＜ 200 I.U/L 6 . Serum creatinine ≦1.5 mg/dl Blood urea nitrogen ( BUN ) ≦ 25 mg/dl 7 . Objectively measurable evaluable disease 8 . Signed informed consent 1 . Age ＞ 75 year , Age ＜ 15 year 2 . Pregnant breastfeed woman . 3 . Patients history brain metastasis CNS involvement . 4 . Child 's class B C patient liver cirrhosis . 5 . Impaired cardiac function NYHA ( New York Heart Association ) classification ≧ GrII . 6 . Concurrent glucocorticoid use ( reason ) . The conventional use glucocorticoid antiemetic purpose also allow .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2005</verification_date>
</DOC>